Attendee search 

We provide life cycle management solutions for innovator and branded pharmaceutical, medical device, biological products manufacturers. This entails winning difficult-to-obtain patents, designing Intellectual Property strategy and enforcing intellectual property to maintain market share.

I will shortly begin to interview companies able to register and launch a new US Rx product outside the US.  Partner companies must have (a) a women's health or rheumatology sales force; (b) experience registering hormone products; and (c) the ability to move quickly. 

From helping Tenet Healthcare stave off a hostile takeover to obtaining summary judgment for a former health care general counsel in a precedent-setting False Claims Act case to establishing ERISA preemption precedent in the United States Supreme Court on behalf of Aetna, achieving successful outcomes for our clients in their most important matters is our singular focus.

Protecsom 

ProtecSom designs smart respiratory drug delivery devices to improve pulmonary drug distribution and patients life.

Industry sectors Medtech Therapeutics Area Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Your innovative solution

Optim'Hal provides real-time information on the drug dose inhaled from a metered dose inhaler with a spacer device. It sends this information to any computer, smartphone or tablet and also converts it as light and sound signals to encourage drug taking among toddlers.

Which problem are you solving ?

Compliance is a major problem with asthma sufferers. Thanks to incentive provided to patients, children and parents, Optim'Hal improves compliance. The inhaled dose and speed of the inspiratory flow are critical to the reliability of the inhaled treatment. Thanks to information about these settings, Optim'Hal' makes the treatment more reliable.

Target market segments

Asthma and COPD sufferers. /Any inhaled treatment. /Research centers about aerosoltherapy.

Key value proposition

Better compliance, thanks to incentive signals or applications depending on the age / Better surveillance, thanks to true data on patient compliance available for caregivers / Improving pulmonary drug distribution thanks to information on inspiratory flow

Company Overview

Provid Pharmaceuticals Inc. was founded to discover novel therapeutics for autoimmune diseases using peptide mimetics technology.   Provid’s strategy has resulted in the discovery of PV-267, a small molecule drug candidate for the treatment of multiple sclerosis (MS) and leads for rheumatoid arthritis and other autoimmune diseases that operate by blocking disease-associated MHC class II molecules.

Provid’s MS drug candidate, PV-267 uniquely inhibits the MHC Class II molecule HLA-DR2b, the most important gene target in the autoimmune disease process in MS.  MS is genetically linked with HLA-DR2b (DRB1*1501).  DR2b is carried by a majority of MS patients (ca. 700,000 worldwide) and binds and presents antigenic myelin fragments to autoreactive T cells, triggering the autoimmune response that damages myelin insulation on nerves, leading to MS disease symptoms and disability.  Provid designed PV-267 to bind tightly and selectively to DR2b, blocking antigen binding.  PV-267 has been shown to disrupt the autoimmune process in MS animal models and in human cells from DR2+ patients.  Because PV-267 does not compromise other aspects of the immune system, its potential for superior safety is a major advantage over current disease-modifying drugs.

Recent data have shown that PV-267 has high oral bioavailability in a proprietary formulation being developed in collaboration with Enteris Biopharma.  Oral efficacy, while not essential to test the concept of the DR2 inhibitory mechanism, is an important factor commercially and for the MS patient.

Early Clinical Trial Concept.  Because of its DR2b antagonist mechanism, it is feasible to assess immunological efficacy in DR2b+ individuals in early clinical trials, greatly reducing the clinical development risk and clearing the path for a targeted phase II efficacy trial.  These studies are being planned by our Clinical Advisory Board under the leadership of Prof. Larry Steinman at Stanford. 

Development Plan. Provid will pursue preclinical and early clinical studies of our DR2b inhibitors and is seeking partnerships with pharma company partners.